LYL797 is a ROR1-targeted CAR T-cell therapy currently being investigated in patients with ROR1 who have pre-treated NSCLC and triple-negative breast cancer (NCT05274451). This evidence concerns the gene ROR1 and triple-negative breast carcinoma.